Moreover, highly aggressive angiosarcomas exhibit considerable genomic plasticity, allowing them to activate alternative signaling pathways (e.g., MET, AXL, and MAS) (13, 16), thereby bypassing VEGFR inhibition by sunitinib. Here, MET is linked to angiosarcoma.